Results 91 to 100 of about 2,492,664 (191)

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study

Cancer Science, EarlyView.
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Takahiro Fujino, Haruya Okamoto, Mitsuhiro Itagaki, Hiroshi Handa, Takayuki Shimizu, Morio Sawamura, Tadao Ishida, Satoru Kosugi, Shuichi Ota, Makoto Yoshimitsu, Yutaka Shimazu, Isamu Sugiura, Hirohiko Shibayama, Shin‐ichi Fuchida, Hiroyuki Takamatsu, Akiko M. Saito, Hitoshi Kiyoi, Koichi Akashi, Itaru Matsumura, Akifumi Takaori‐Kondo, Junya Kuroda, Shinsuke Iida   +24 more
wiley   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler, Simon Lüdtke, Lena Dietze, Marie Schiffmann, Dominik Straube, Jan Ehrchen   +5 more
wiley   +1 more source

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia

, 2022
Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia.
Fotiou, D., Theodorakakou, F., Kastritis, E.   +2 more
core  

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Role of ofatumumab in treatment of chronic lymphocytic leukemia

Journal of Blood Medicine, 2011
Marays Veliz, Javier Pinilla-IbarzH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAAbstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal ...
Veliz M, Pinilla-Ibarz J
doaj  

Charting the course of Sjögren's disease: A historical analysis of scientific progress

European Journal of Oral Sciences, EarlyView.
Abstract Sjögren's disease (SjD) bears the name of the Swedish ophthalmologist Henrik Sjögren. His 1933 doctoral thesis on keratoconjunctivitis sicca ignited interest, yet much remains under debate. SjD is an autoimmune disorder that primarily affects the exocrine glands, particularly the salivary and lacrimal glands, leading to a dryness of the eyes ...
Diego Ustárroz Cantali, Fabiola Reis de Oliveira, Denise Cantarelli Machado, Moisés Evandro Bauer   +3 more
wiley   +1 more source

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Biologics: Targets & Therapy, 2015
Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab
Cerquozzi S, Owen C
doaj